Isoimperatorin

产品说明书

Print
Chemical Structure| 482-45-1 同义名 : -
CAS号 : 482-45-1
货号 : A172258
分子式 : C16H14O4
纯度 : 95%
分子量 : 270.28
MDL号 : MFCD00272155
存储条件:

Pure form Sealed in dry, 2-8°C

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 2 mg/mL(7.4 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

无水乙醇: 8 mg/mL(29.6 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇

动物实验配方:
生物活性
描述 Isoimperatorin is a methanolic extract of the roots of Angelica dahurica shows significant inhibitory effects on acetylcholinesterase (AChE) with the IC50 of 74.6 μM[3]. Isoimperatorin demonstrated significant inhibitory activity (IC50 36.43 μM) against urease without cytotoxic effects. Isoimperatorin showed the highest expression level of type II collagen at 368.87 μM. The docking results confirmed strong binding affinity with the target protein[4]. Moreover, isoimperatorin inhibited the proliferation of SGC-7901 cells in a dose- and time-dependent manner, and the half maximal inhibitory concentration was 18.75 µg/ml[5].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.70mL

0.74mL

0.37mL

18.50mL

3.70mL

1.85mL

37.00mL

7.40mL

3.70mL

参考文献

[1]Tong K, Xin C, Chen W. Isoimperatorin induces apoptosis of the SGC-7901 human gastric cancer cell line via the mitochondria-mediated pathway. Oncol Lett. 2017 Jan;13(1):518-524.

[2]Kim DK, Lim JP, et al. Acetylcholinesterase inhibitors from the roots of Angelica dahurica. Arch Pharm Res. 2002 Dec;25(6):856-9.

[3]Kim DK, Lim JP, Yang JH, Eom DO, Eun JS, Leem KH. Acetylcholinesterase inhibitors from the roots of Angelica dahurica. Arch Pharm Res. 2002 Dec;25(6):856-9.

[4]Raza H, Abbas Q, Hassan M, Eo SH, Ashraf Z, Kim D, Phull AR, Kim SJ, Kang SK, Seo SY. Isolation, characterization, and in silico, in vitro and in vivo antiulcer studies of isoimperatorin crystallized from Ostericum koreanum. Pharm Biol. 2017 Dec;55(1):218-226.

[5]Tong K, Xin C, Chen W. Isoimperatorin induces apoptosis of the SGC-7901 human gastric cancer cell line via the mitochondria-mediated pathway. Oncol Lett. 2017 Jan;13(1):518-524.